X

Trial Profile

Phase IIb trial of TG 4001 (tipapkinogene sovacivec) in patients with HPV16-positive oropharyngeal squamous cell carcinomas.

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tipapkinogene sovacivec (Primary) ; Antineoplastics
Indications Human papillomavirus infections; Oropharyngeal cancer
Focus Therapeutic Use
Sponsors Transgene

Most Recent Events

24 Mar 2015 Status changed from planning to discontinued, based on a Transgene media release.
21 Nov 2012 New trial record
13 Nov 2012 First safety and efficacy results are expected to be available in 2016, according to a Transgene media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com